Skip to content Skip to footer

Join Our On-Demand Webinar, with Dr. Brian Bobb & Annie Bell, PA-C on Antibiotic Stewardship in Outpatient Care.

Menu Close
Close
Contact Us

A Paradigm
Shift in Point-of-Care Respiratory Assessment

Rapid differentiation between Bacterial vs Non-Bacterial Infections

Febridx_product_box
Learn More
Discuss FebriDx for Your Practice

Fingerstick Point-of-Care Test

Results in 10-15 Minutes

FDA Cleared

NPV to Rule Out Bacterial Infection¹

Supports Antibiotic Stewardship

Supports Urgent Care and ER Workflows

How FebriDx® Works

FebriDx uses a proprietary combination of two host immune response biomarkers CRP and MxA to aid clinicians in distinguishing bacterial infection from non-bacterial etiology at the point of care.

CRP (C-Reactive Protein)

CRP is an acute-phase inflammatory protein that rises in response to infection and systemic inflammation. It elevates rapidly within hours of infection and reflects the severity of the inflammatory response, but alone remains non-specific for bacterial infection at lower thresholds.

MxA (Myxovirus Resistance Protein A)

MxA is an innate immune biomarker that elevates specifically in response to acute viral infection. It is not elevated in bacterial infections and demonstrates rapid induction with a prolonged half-life, making it a reliable indicator of viral immune activation.

Individually, CRP and MxA are insufficient to differentiate bacterial from non-bacterial illness.
Together, they provide the clinical sensitivity and specificity needed to support respiratory decision-making.

By combining a marker of systemic inflammation (CRP) with a virus-specific immune marker (MxA), FebriDx delivers actionable insight into the underlying immune response driving acute respiratory illness¹.

Backed by Peer-Reviewed Evidence

Annals of Medicine

18 Apr 2018

Published in 18 May 2018

A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever

Shapiro, N. I., Self, W. H., Rosen, J., Sharp, S. C., Filbin, M. R., Hou, P. C., Sambursky, R.

Conclusion
View Study

Open Forum Infectious Diseases

2017 Nov 3

Published in 2018 Feb

Outpatient Antibiotic Stewardship: A Growing Frontier—Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use

Joseph P, Godofsky E.

Conclusion
View Study

Journal of Clinical Medicine

14 Aug 2017

Published in 7 October 2017

Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections

Self, W.H.; Rosen, J.; Sharp, S.C.; Filbin, M.R.; Hou, P.C.; Parekh, A.D.; Kurz, M.C.; Shapiro, N.I.

View Study
1
2
3
4
5
6
7
8
9
10
11

Supporting
Antibiotic Stewardship

In acute respiratory care, lack of real-time diagnostic clarity often leads to unnecessary antibiotic prescribing.
FebriDx addresses that gap by providing rapid immune-response insight at the point of care , supporting more confident, evidence-aligned treatment decisions.

Multiple peer-reviewed studies demonstrate that FebriDx-guided management can:

  • 1
    Reduce
    Reduce unnecessary antibiotic use when bacterial infection is unlikely².
  • 2
    Improve
    Improve clinician confidence in treatment decisions².
  • 3
    Support
    Support stewardship initiatives across urgent care and emergency settings².

Demonstrated Economic Value in Acute Respiratory Care

Beyond clinical impact, published health economic models suggest FebriDx-guided care may significantly reduce the overall cost burden of acute respiratory infections (ARIs).

  • 1
    ~$8.25 billion
    Estimated annual U.S. cost of ARI management under standard-of-care³.
  • 2
    ~$5.74 billion
    Estimated cost with FebriDx-guided management³.
  • 3
    ~$2.5 billion
    Potential annual system-wide savings³.

Sensitivity analysis (changing assumptions within ±20%) showed the potential savings ranged from as low as US $0.08 billion to as high as US $3.27 billion, indicating savings persist across a range of plausible scenarios, but depend on key variables like test sensitivity, prevalence, and population size³.

Empowered by compassion

Enhancing health through care

At Healer, we are committed to providing exceptional healthcare that prioritizes patient well-being. Our experienced team works collaboratively to create personalized treatment plans that cater to individual needs.

Empowering you with expert care and personalized support to take control of your well-being every step of the way.

Medical consult

Expert medical advice tailored to your needs.

Medical records

Secure and seamless access to your health data anytime.

Emergency help

Fast and reliable support in urgent medical situations.

Pharmacy care

Easy and reliable access to essential medications.

Order Through Dx Direct Today.

Dx Direct is built to eliminate the operational, administrative, and adoption barriers that slow down point-of-care innovation, helping clinical teams evaluate, implement, and use FebriDx confidently in real-world care settings.

  • 1
    Before You Order: Clinical & Operational Confidence
  • 2
    At the Point of Purchase: Speed & Simplicity
  • 3
    After Go-Live: Ongoing Support That Actually Matters

Why Providers Choose Dx Direct?

Authorized & Preferred Distribution Partner

Direct alignment with Lumos Diagnostics — no gray market risk, no uncertainty

Dedicated FebriDx
Focus

Not a catalog reseller. One product. One mission. Deep expertise.

Low-Friction
Ordering

Streamlined purchasing designed for urgent care, EDs, and outpatient workflows

Subscription & Volume-Aligned Pricing

Predictable supply, reduced reordering burden, discounted pricing for committed usage

Education-First Support

Clear clinical context, onboarding guidance, and implementation support

Reimbursement & Documentation Resources

Practical support to help teams navigate billing and internal justification

We’re more comfortable not prescribing antibiotics when the test supports it. It helps align our decisions with stewardship goals without slowing down care.
Dr. Anjali Patel, DO

Urgent Care Physician

Having a tangible result makes conversations with patients much easier. It’s no longer just an explanation — we can show them why antibiotics aren’t needed.
Dr. James Reynolds, MD

Emergency Medicine Physician

Implementation was straightforward. Training was minimal, and our staff were comfortable using it quickly.
Lisa Gomez, RN

Clinic Manager

It’s easy to find a vendor. It’s much harder to find a team that actually helps when you’re using something day-to-day. Dx Medical Solution has been consistently available when we’ve needed guidance.
Jason Miller

Operations Manager, Urgent Care Group

One of the biggest benefits has been how it changes patient conversations. When we can show a result, patients better understand the decision, and there’s noticeably less pushback around antibiotics.
Dr. Steven Morales, MD

Urgent Care Physician

“ FebriDx provides a
tangible, visual result
that clinicians can
share during
the visit. ”

Talk to Our Team
For Clinical Information & Ordering Support
Order FebriDx Now

By the numbers

At Healer, we are proud to share our impact on the community through healthcare services.

0%

Loyal clients

0+

Patients treated

0

Years

0+

Patients treated

0

Wellness starts

0

Community reach
Step-by-step

Clear steps to get started now

  • 1
    Personalized care
    We tailor treatment plans to each patient’s unique health needs for the best outcomes.
  • 2
    Advanced technology
    Our clinic uses cutting-edge equipment and techniques for accurate diagnosis and effective treatment.
  • 3
    Experienced specialist
    Our skilled medical team brings years of expertise to provide top-quality healthcare.
Common questions

Frequently asked questions

FebriDx is FDA cleared, It is cleared for use by healthcare professionals to support clinical decision-making in acute respiratory infections. Learn More about FDA Clearance here

FebriDx measures the host immune response, not a specific pathogen, using two biomarkers:

  • MxA → associated with viral infection
  • CRP → associated with bacterial infection

No. FebriDx is not a standalone diagnostic and does not replace clinical judgment.
Results should always be interpreted in the context of clinical signs, symptoms, and patient history.

Results are available in approximately 10–15 minutes, while the patient is still in the room.

FebriDx uses a simple fingerstick capillary blood sample. No venipuncture. No lab send-out.

No. FebriDx is designed for front-line acute care, including:

  • Urgent care
  • Emergency departments
  • Primary care and outpatient respiratory assessment

By helping differentiate bacterial vs non-bacterial immune responses, FebriDx can support more confident treatment decisions and reduce unnecessary antibiotic use when bacterial infection is unlikely.

No. FebriDx does not detect specific pathogens. It evaluates the body’s immune response, which is a different clinical question.

Yes. FebriDx has been studied in pediatric emergency settings and has demonstrated clinical utility in supporting antibiotic decision-making in children with febrile acute respiratory infections.(12-60)

FebriDx can be ordered directly through Dx Direct, the preferred and dedicated Lumos Diagnostics partner, offering fast ordering, reliable delivery, and ongoing support.

👉 Contact FebriDx Direct to order

Dx Direct provides reimbursement support resources and guidance, but does not guarantee reimbursement. Coverage and payment are subject to payer policies.

FebriDx uses a CRP threshold of ≥20 mg/L to help minimize low-level, non-specific inflammation. However, CRP can be elevated in some non-infectious conditions, which is why FebriDx results must always be interpreted in the context of clinical history and examination.

FebriDx is listed on the CMS Clinical Laboratory Fee Schedule (CLFS) with a national reimbursement rate of $41.38 per test.

FebriDx is FDA cleared for patients aged 12–60 years and has demonstrated clinical utility in adolescent acute care settings when used alongside clinical judgment.

FebriDx tests can be stored at room temperature (4-25°C or 39-77°F).

The test is most appropriate when: Symptoms have been present for 7 days or less The patient is within 3 days of fever onset This timing aligns with the expected immune-response window for the biomarkers measured by FebriDx and supports more reliable clinical interpretation.

FebriDx is designed for ease of use by trained healthcare professionals. Dx Direct provides education and implementation support to ensure smooth adoption

The CPT (Current Procedural Terminology) PLA (Proprietary Laboratory Analyses) code for the FebriDx test is 0442U

Clinical Operations Journal
 by Dx Direct

Dx Direct

FDA Approved vs. FDA Cleared: Understanding the Key Difference You Need to Know

June 4, 2025•No Comments•
Antibiotic Stewardship

Why Distinguishing Viral vs. Bacterial Infections Remains a Challenge in Urgent Care

June 4, 2025•2 Comments•

Have inquiries? Reach out to us!

[1] Shapiro, N. I. et al. (2018) ‘A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever’, Annals of Medicine, 50(5), pp. 420–429. doi: 10.1080/07853890.2018.1474002.

[2] Wilcox, Christopher R et al. “Use of the FebriDx® host-response point-of-care test may reduce antibiotic use for respiratory tract infections in primary care: a mixed-methods feasibility study.” The Journal of antimicrobial chemotherapy vol. 79,6 (2024): 1441-1449. doi:10.1093/jac/dkae127

[3] Dick, Katherine, and John Schneider. “Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States.” Journal of health economics and outcomes research vol. 8,2 56-62. 30 Sep. 2021, doi:10.36469/001c.27753

Webinar